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1015-9584/Copyright ª 2015, Asian SuSummary Background/Objective: To investigate the influence of serum anti-thyroglobulin
antibody (TgAb) on the prognosis in papillary thyroid cancer (PTC) patients.
Methods: In this retrospective study, the participants were enrolled from 1206 PTC patients
(927 women, 279 men; mean age, 42.2 years) with T2 and higher, or N1 or M1 classifications
in tumorenodeemetastasis staging after total thyroidectomy. We recorded the final serum
TgAb data (on thyroxin therapy) at the end of follow-up in 2012. Patients were classified as
negative TgAb or positive TgAb groups on the basis of their serum TgAb levels (< 70 IU/mL
or  70 IU/mL).
Results: Among the 1206 patients, after mean follow-up for 11.6  6.1 years (range, 2.0e29.2
years), there were 75 with positive TgAb and 1131 with negative TgAb. Patient categorization
depending on the follow-up time (2e5 years after surgery, 5e10 years after surgery, and 10e30
years after surgery) was performed. In comparison to traditional risk factors, such as age, tu-
mor size, and sex, which were important prognostic factors for cancer recurrence and mortal-
ity in PTC patients, there was no significant difference in the prognosis between positive TgAbeclare that there are no conflicting financial interests.
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total thyroidectomy, Asian Journal opatients and negative TgAb patients by the multivariate analyses (cancer recurrence,
p Z 0.164, p Z 0.112, p Z 0.202, respectively; cancer mortality, p Z 0.181, p Z 0.646,
p Z 0.656, respectively) based on the different follow-up times.
Conclusion: Positive serum TgAb was not a risk factor, and was not associated with the prog-
nosis of PTC patients.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Serum thyroglobulin (Tg) level is an important marker in the
follow-up of differentiated thyroid cancer (DTC) patients
after total thyroidectomy, and it serves as an indicator for
cancer recurrence.1,2 However, it was estimated 10e29%
DTC patients may have anti-thyroglobulin antibody
(TgAb).3e5 The presence of TgAb is higher in DTC patients,
compared with the general population.3,6 TgAb is produced
as the result of the presence of thyroid tissue; in addition,
the presence of TgAb may influence the measurement of
serum Tg levels,7 making the serum Tg levels unreliable.
Therefore, the current guideline suggests that all specimens
sent for Tg measurement require adjunctive TgAb testing.8
Previous studies show that, after total thyroidectomy,
serum TgAb gradually declines over years.5,9 A markedly
rising trend in TgAb concentrations during follow-up or
persistently high TgAb levels of DTC patients might indicate
cancer recurrence or persistence.10e12 Otherwise, con-
flicting data exist concerning the association of serum TgAb
levels after surgery and disease activity in DTC patients
after long-term follow-up period.5,6,13 The aim of this study
is to realize whether the presence of high serum TgAb
during follow-up is a prognostic factor in patients with
papillary thyroid cancers (PTCs).
2. Methods
2.1. Study participants
During the period 1983e2012, a total of 2118 PTC patients
with TgAb data underwent treatment and follow-up in
Chang Gung Medical Center in Linkou and Keelung, Taiwan.
We recruited patients of tumorenodeemetastasis (TNM)
staging with T2 and higher, or N1 or M1 after total or
complete thyroidectomy. Tumor stage had been classified
according to the International Union against Cancer TNM
criteria (6th edition).14 The enrolled patients were high risk
group (any T3 and T4, or any Twith N1 or M1 in TNM staging)
based on European consensus for the management of DTC
patients. In addition, we also included patients with
T2N0M0 as most of them had gone total thyroidectomy in
our hospital. Patients with T1N0M0 (tumor size,  2 cm)
were excluded from the study because the majority of the
patients categorized in T1N0M0 did not undergo total thy-
roidectomy. Permission was obtained from the Institutional
Review Board (IRB) and Ethics Committees of Chang Gung
Memorial Hospital for a retrospective review of the medicalo S-F, et al., Prognosis of papillar
f Surgery (2015), http://dx.doi.orecords of study participants. The IRB waived the require-
ment for obtaining informed consent. Confidentiality of the
research participants was maintained in accordance with
the requirements of the IRB of Chang Gung Memorial Hos-
pital. All work was conducted in accordance with the
principles of the Declaration of Helsinki.
2.2. Follow-up
The patients were treated and followed-up at Chang Gung
Medical Center with a minimum postoperative follow-up
duration of 2 years. All the patients underwent total or
complete thyroidectomy followed by immediate I-131
remnant ablation. We recorded the patients’ last serum
TgAb levels (on thyroxin therapy) after the mean follow-up
of 11.6  6.1 years. The term total thyroidectomy refers to
total or near total thyroidectomy with or without central
compartment and selective bilateral neck lymph node
dissection.
Serum stimulated Tg was measured 1 month post-
operatively without thyroxine treatment, and serum Tg,
TgAb, and TSH were measured every 3e6 months during
thyroxine supplementation. The patients underwent neck
ultrasound examination every 6e12 months. Once recur-
rent lesions were suspected, subsequent larger dose of I-
131 were used for treatment. Surgical treatment was per-
formed whenever localized lesions were confirmed. Some
patients underwent surgery or I-131 ablation therapy more
than once after active thyroid cancer was diagnosed.
External beam radiation therapy was used in a few cases of
advanced local recurrence or distant bony metastasis.
2.3. Assessment
Patients were classified into negative or positive TgAb
groups according to serum TgAb levels (< 70 IU/mL or 
70 IU/mL) at last follow-up data in 2012, and influence of
serum TgAb level on prognostic outcome was evaluated. In
our institution, TgAb was measured by a competitive
radioimmunoassay (Biocode, Lie`ge, Belgium). The analyt-
ical sensitivity is 6 IU/mL. The functional sensitivity is
measured with a precision of maximum 20% interassay
variance and the value is < 15 IU/mL. Interassay precision
was mean 90.3 IU/mL: coefficient of variation (CV) 9.3%;
390.0 IU/mL: CV 12.8%; and 985.4 IU/mL: 10.6%. Intra-assay
precision was mean 72.6 IU/mL: CV 8.3%; 345.7 IU/mL: CV
7.1%; and 889.9 IU/mL: CV 5.7%. In this study, the
manufacturer-recommended cutoff was used in our labo-
ratory. Positivity for TgAb was > 70 IU/mL as suggestedy thyroid cancers with positive serum thyroglobulin antibody after
rg/10.1016/j.asjsur.2015.08.002
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immunoradiometric kit (CisBio International, CIS Bio Inter-
national, France, France). The detection limit of the Tg kit
is 0.5 ng/mL, and its functional sensitivity has been
assessed in our laboratory to be 1.2 ng/mL. The interassay
CV was 8.0% at a Tg level of 4.9 ng/mL, 6.9% at a Tg level of
223.2 ng/mL, and 5.1% at a Tg level of 312.9 ng/mL. Normal
levels of serum Tg in our laboratory were estimated to
be < 25 ng/mL. The Tg level was considered accurate only
if the recovery test (performed on all serum samples) was <
80%. Cancer recurrence in this study included recurrence
and persistent disease. Recurrence was defined as the
reappearance of disease 1 year after total thyroidectomy
and was confirmed by neck ultrasound with positive
cytology or histopathological findings or extrathyroid I-131Figure 1 Clinical follow-up of the 1206 patients and ther
anti-thyroglobulin antibody (TgAb) level at the end of follow-up in
Please cite this article in press as: Kuo S-F, et al., Prognosis of papillar
total thyroidectomy, Asian Journal of Surgery (2015), http://dx.doi.oruptake on whole body scanning, fluorine-18 fluorodeox-
yglucose positron emission tomography, magnetic reso-
nance imaging, or computed tomography. Persistent
disease was defined as the reappearance of disease within 1
year after total thyroidectomy and was confirmed by neck
ultrasound with positive cytological or surgical histopatho-
logical findings or extrathyroid I-131 uptake on whole body
scanning, fluorine-18 fluorodeoxyglucose positron emission
tomography, magnetic resonance imaging, or computed
tomography.
2.4. Statistical analysis
Discrete data are reported as absolute frequency and per-
centages, and compared using Chi-squared or Fisher’s exactapeutic outcomes of the patients based on their serum
2012.
y thyroid cancers with positive serum thyroglobulin antibody after
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+ MODELtests, where appropriate. Continuous data are reported as
means and standard deviation and compared using a Stu-
dent t test or ManneWhitney U test, where appropriate.
Multivariate analyses were performed using a logistic
regression model to identify the association of TgAb with
cancer recurrence or cancer mortality after adjusting for
other clinicopathological predictors, including age, sex, I-
131 treatment dose, and tumor size. All tests were two-
tailed, and p < 0.05 was considered statistically signifi-
cant. All statistical analyses were performed using the SPSS
for Windows version 15.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Study populations
In total, 1206 PTC patients after total thyroidectomy with
TgAb data were recruited in the study. There were 927
women and 279 men with a mean age of 42.2  15.3 years.
All the patients were followed until the end of 2012 or the
date of death.
3.2. Clinical outcomes
Figure 1 shows the follow-up of the 1206 patients and their
clinical outcomes. A total of 75 patients (6.2%) presented
with positive TgAb ( 70 IU/mL) and 1131 patients (93.8%)
presented with negative TgAb (< 70 IU/mL) at the end of
follow-up. There were 235 (19.5%) with cancer recurrence,
75 (6.2%) with cancer mortality after the mean follow-up of
11.6  6.1 years (range, 2e27.2 years).
Because the follow-up time for the patients varied, pa-
tient categorization was further performed depending on
the follow-up time: 2e5 years after surgery, 5e10 years
after surgery, and 10e30 years after surgery. Tables 1e3Table 1 Clinical features of papillary thyroid carcinoma pati
(TgAb) during the follow-up period 2e5 years after surgery.
Total Nega
Number n Z 276 n Z
TgAb (positive) 18 (6.5%)
Age (y) 48.8  15.7 (48; 14e84) 49.4
Sex, Female 193 (69.9) 177 (
Male 83 (30.1) 81 (3
Tumor size (cm) 3.4  1.6 (3.0; 0.5e11.1) 3.4 
Postoperative stimulated
Tg level (ng/mL)
633  4678 (4.2; 0e65,320) 677 
TNM staging,
stages I/II/III/IV (%)
119/38/90/29
(43.1/13.8/32.6/10.5)
109/3
(42.2
Total I-131 therapeutic
dose (mCi)
64  87 (30; 0e600) 64 
Follow-up (y) 3.1  1.0 (3.0; 1.1e5.0) 3.1 
Cancer recurrence 68 (24.6) 63 (2
Cancer mortality 42 (15.2) 39 (1
Data are presented as means  standard deviation (median; range) o
Tg Z thyroglobulin; TNM Z tumorenodeemetastasis.
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total thyroidectomy, Asian Journal of Surgery (2015), http://dx.doi.ocompare the clinical characteristics between positive and
negative TgAb patients based on the different follow-up
time. The tumor size, sex, total I-131 treatment dose dur-
ing follow-up, and TNM staging were not statistically
different between positive and negative TgAb patients
based on the different follow-up time, but the patients
with positive TgAb during the follow-up period 2e5 years
after surgery were younger. The rate of cancer recurrence
and cancer mortality between positive and negative TgAb
patients were not statistically different based on the
different follow-up time.
By the multivariate analyses (Tables S1eS3), sex, tumor
size at initial diagnosis, and total I-131 treatment dose
during follow-up were not related to positive TgAb at the
end of follow-up, but being younger patients was associ-
ated with positive TgAb during the follow-up period 2e5
years after surgery.
3.3. Multivariate analysis of association between
TgAb, cancer recurrence, and cancer mortality
Based on the different follow-up times (2e5 years, 5e10
years, and 10e30 years after surgery), Tables 4e6 sum-
marize the results of multivariate analyses for association
of TgAb with cancer recurrence and cancer mortality after
adjusting for other clinicopathological predictors, including
age, sex, total I-131 treatment dose, and tumor size. The
results indicate that traditional risk factors, such as older
age and larger tumor size are good predictors for cancer
recurrence and cancer mortality. Male sex was also asso-
ciated with poor prognosis in PTC patients with statistical
significance. By contrast, positive serum TgAb levels did not
increase the risk of cancer recurrence (p Z 0.164,
p Z 0.112, p Z 0.202) or cancer mortality (p Z 0.181,
p Z 0.646, p Z 0.656) in PTC patients during the different
follow-up time.ents with negative and positive anti-thyroglobulin antibody
TgAb p
tive Positive
258 n Z 18
 15.8 (48; 14e84) 40.2  10.9 (39.5; 20e58) 0.016
68.6) 16 (88.9) 0.700
1.4) 2 (11.1)
1.6 (3.0; 0.5e11.1) 3.3  1.5 (2.75; 1.2e6.0) 0.897
4836 (4.3; 0e65,320) 3.5  4.9 (0; 0e14.8) 0.556
6/87/26
/14.0/33.7/10.1)
10/2/3/3
(44.6/11.1/16.7/16.7)
0.394
88 (30; 0e600) 63  69 (45; 0e300) 0.950
1.0 (3.0; 1.1e5.0) 3.2  1.1 (2.9; 1.3e4.8) 0.622
4.4) 5 (27.8) 0.779
5.1) 3 (16.7) 0.743
r n (%), unless otherwise indicated.
y thyroid cancers with positive serum thyroglobulin antibody after
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Table 2 Clinical features of papillary thyroid carcinoma patients with negative and positive anti-thyroglobulin antibody
(TgAb) during the follow-up period 5e10 years after surgery.
TgAb p
Total Negative Positive
Number n Z 330 n Z 309 n Z 21
TgAb (positive) 21 (6.4%)
Age (y) 43.7  15.1 (42; 11e83) 43.7  15.3 (41; 11e83) 44.1  12.9 (44; 23e66) 0.912
Sex, Female 256 (77.6) 238 (77) 18 (85.7) 0.431
Male 74 (22.4) 71 (23) 3 (14.3)
Tumor size (cm) 3.1  1.3 (2.8; 0.2e10.0) 3.0  1.3 (2.8; 0.2e10.0) 3.2  1.3 (2.7; 1.5e7.0) 0.704
Postoperative stimulated
Tg level (ng/mL)
190  1085 (4.15; 0e12,094) 202  1120 (4.54; 0e12,094) 19  83
(0; 0e381)
0.456
TNM staging,
stages I/II/III/IV (%)
141/41/133/15
(42.7/12.4/40.3/4.5)
134/38/124/13
(43.4/12.3/40.1/4.2)
7/3/9/2
(33.3/14.3/42.9/9.5)
0.766
Total I-131 therapeutic
dose (mCi)
129  205 (60; 0e1800) 130  205 (60; 0e1800) 116  216
(60; 29.7e1032.3)
0.766
Follow-up (y) 7.8  1.5 (8.0; 5.1e10.0) 7.8  1.5 (8.0; 5.1e10.0) 8.1  1.5 (8.25; 5.1e10.0) 0.395
Cancer recurrence 56 (17.0) 52 (16.8) 4 (19.0) 0.766
Cancer mortality 14 (4.2) 13 (4.2) 1 (4.8) 0.609
Data are presented as means  standard deviation (median; range) or n (%), unless otherwise indicated.
Tg Z thyroglobulin; TNM Z tumorenodeemetastasis.
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In our laboratory, serum Tg was measured using an immu-
nometric assay method that was prone to interference by
TgAb, which might cause an underestimation of serum Tg
levels.3e5,7 The manufacturer-recommended cutoff for
TgAb was used in this study and the results of the study
showed that the presence of positive TgAb during the
different follow-up times (2e5 years, 5e10 years, andTable 3 Clinical features of papillary thyroid carcinoma pati
(TgAb) during the follow-up period 10e30 years after surgery.
Total Nega
Number n Z 600 n Z
TgAb (positive) 36 (6.0%)
Age (y) 38.3  14.0 (36; 2e75) 38.3
Sex, Female 478 (79.7) 450 (
Male 122 (20.3) 114 (
Tumor size (cm) 3.3  1.5 (3.0; 0.5e20.0) 3.3 
Postoperative stimulated
Tg level (ng/mL)
44  263 (6; 0e5832) 46 
TNM staging,
stages I/II/III/IV (%)
301/92/192/15
(50.2/15.3/32.0/2.5)
287/8
(50.9
Total I-131 therapeutic
dose (mCi)
168  217 (100; 0e2060) 168 
Follow-up (y) 15.6  4.2 (14.7; 10.1e30.2) 15.7
Cancer recurrence 111 (18.5) 103 (
Cancer mortality 19 (3.2) 16 (2
Data are presented as means  standard deviation (median; range) o
Tg Z thyroglobulin; TNM Z tumorenodeemetastasis.
Please cite this article in press as: Kuo S-F, et al., Prognosis of papillar
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size, or total I-131 treatment dose.
Previous study by Go¨rges et al5 reported that 15% of pa-
tients had TgAb at 1 year and < 10% at 3 years of follow-up.
There was no report of TgAb level after> 10 years follow-up
as our finding. Our study found a frequency of 6.2% for
positive TgAb with mean follow-up of 11.6  6.1 years
(range, 2.0e29.2 years) in PTC patients. Theoretically, TgAb
is produced because of the presence of thyroglobulin;ents with negative and positive anti-thyroglobulin antibody
TgAb p
tive Positive
564 n Z 36
 14.2 (36; 2e75) 38.2  11.7 (37; 19e65) 0.967
79.8) 28 (77.8) 0.771
20.2) 8 (22.2)
1.5 [3.0; 0.5e20.0] 3.1  1.7 (2.8; 1.0e10.0) 0.589
271 (6; 0e5832) 13  31 (0; 0e165) 0.460
2/182/13
/14.5/32.3/2.3)
14/10/10/2
(38.9/27.8/27.8/5.6)
0.090
218 (100; 0e2060) 171  201 (100; 0e885) 0.929
 4.2 (14.8; 10.1e30.2) 14.4  3.3
(14.1; 10.1e24.7)
0.039
18.3) 8 (22.2) 0.553
.8) 3 (8.31) 0.099
r n (%), unless otherwise indicated.
y thyroid cancers with positive serum thyroglobulin antibody after
g/10.1016/j.asjsur.2015.08.002
Table 4 Multivariate regression analysis of the impact of positive or negative serum anti-thyroglobulin antibody (TgAb) levels
on cancer recurrence and mortality during the follow-up period 2e5 years after surgery.
Cancer recurrence Cancer mortality
Odds ratio 95% CI p Odds ratio 95% CI p
lower upper lower upper
TgAb 0.399 0.109 1.457 0.164 2.825 0.616 12.954 0.181
Age 1.041 1.017 1.066 0.001 0.938 0.911 0.967 < 0.001
Sex 0.504 0.243 1.045 0.065 1.438 0.621 3.329 0.397
I-131 dose 1.016 1.011 1.022 < 0.001 0.995 0.991 0.999 0.008
Tumor size 1.259 1.028 1.534 0.026 0.680 0.539 0.589 0.001
CI Z confidence interval.
Table 5 Multivariate regression analysis of the impact of positive or negative serum anti-thyroglobulin antibody (TgAb) levels
on cancer recurrence and mortality during the follow-up period 5e10 years after surgery.
Cancer recurrence Cancer mortality
Odds ratio 95% CI p Odds ratio 95% CI p
lower upper lower upper
TgAb 0.330 0.084 1.297 0.112 1.854 0.123 25.860 0.646
Age 1.030 1.003 1.057 0.027 0.899 0.848 0.954 < 0.001
Sex 0.507 0.210 1.223 0.131 13.467 3.032 59.810 0.001
I-131 dose 1.009 1.006 1.012 < 0.001 0.998 0.996 1.000 0.040
Tumor size 1.119 0.835 1.498 0.451 1.252 0.803 1.952 0.321
CI Z confidence interval.
Table 6 Multivariate regression analysis of the impact of positive or negative serum anti-thyroglobulin antibody (TgAb) levels
on cancer recurrence and mortality during the follow-up period 10e30 years after surgery.
Cancer recurrence Cancer mortality
Odds ratio 95% CI p Odds ratio 95% CI p
lower upper lower upper
TgAb 0.492 0.166 1.462 0.202 3.653 0.853 15.642 0.081
Age 0.982 0.962 1.002 0.080 0.954 0.920 0.991 0.014
Sex 0.671 0.351 1.284 0.228 3.384 1.209 9.470 0.020
I-131 dose 1.008 1.006 1.010 < 0.001 0.998 0.996 0.999 < 0.001
Tumor size 1.283 1.076 1.532 0.006 0.901 0.705 1.152 0.406
CI Z confidence interval.
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+ MODELtherefore, the presence of TgAb may indicate recurrent or
persistent disease in DTC patients after total thyroi-
dectomy.15e17 Progressively elevated serum TgAb levels may
specifically serve as a marker of the presence of cancer
recurrence in DTC patients with low or undetectable serum
Tg levels.10e12 However, the clinical significance of post-
operative serum TgAb levels as a prognostic marker is
controversial.5,6,13 After total or complete thyroidectomy,
close follow-up and aggressive I-131 therapy for high-risk
DTC patients without underestimating falsely low Tg
values in TgAb-positive patients are important work. In this
long-term study, we found that serum TgAb levels during
follow-up were unable to predict cancer recurrence or
cancer mortality. Although there were no other outcome
studies in PTC patients focusing on serum TgAb levels during
long-term follow-up, the finding was comparable to thePlease cite this article in press as: Kuo S-F, et al., Prognosis of papillar
total thyroidectomy, Asian Journal of Surgery (2015), http://dx.doi.oresult of Go¨rges et al5 that neither the initial TgAb levels nor
the presence of circulating TgAb at the 15e18 month eval-
uation was associated with the progression of the disease in
DTC patients. On the contrary, there was an another study in
which they found PTC patients with positive serum TgAb
titer during the 1st year after primary treatment were more
likely to have persistent or recurrent disease than those who
were consistently TgAb-negative.18 However, there is
growing recognition that it is the trend in TgAb concentra-
tions that is more prognostic than the presence or absence of
TgAb. Sequential TgAb change after total thyroidectomy,
changes of serum TgAb levels before and 1e2 years after
thyroidectomy, and serum TgAb levels measured at 6e12
months after remnant ablation are all useful for prediction
of clinical outcomes in patients with DTC in several recent
reports.19e21y thyroid cancers with positive serum thyroglobulin antibody after
rg/10.1016/j.asjsur.2015.08.002
Prognosis of PTC with positive TgAb 7
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received equally close follow-up and received comparable
I-131 dose for ablation therapy, and had comparable clin-
ical outcome. In contrast to serum TgAb levels, large tumor
size, and older age, which have long been regarded as good
prognostic factors for patients with differentiated thyroid
cancer,14,22e24 were closely associated with cancer recur-
rence and cancer mortality as well in our study.
There were limitations in this study. TgAb assay was not
performed in euthyroid and non-DTC patients in the study.
There were only 75 TgAb-positive patients, which might be
insufficient to detect differences in prognostic outcome
between TgAb-positive and TgAb-negative patients. In
addition, we have no data regarding the trend of serum
TgAb level, which would be more informative than pres-
ence or absence of TgAb.
In summary, unlike traditional risk factors, such as age,
tumor size, and serum Tg levels, which are important
prognostic factors for cancer recurrence and mortality in
PTC patients, positive serum TgAb during follow-up was not
related to the prognosis of PTC patients.
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